Novartis' Cosentyx Shows Improvements In Signs And Symptoms For Both AS And PsA

Announced data showing Cosentyx or secukinumab shows sustained improvements in the signs and symptoms for active ankylosing spondylitis (AS) at 3 years, consistent with previous findings in active psoriatic arthritis (PsA) at 3 years. New data also show Cosentyx provides rapid and sustained pain relief in patients with active PsA out to 2 years.

Cosentyx is the only fully human interleukin-17A (IL-17A) inhibitor to demonstrate 3-year efficacy and safety in Phase III studies of both AS and PsA, which are life-long debilitating inflammatory diseases. Cosentyx is also used to treat moderate-to-severe psoriasis, which is significant as up to 8 in 10 patients with PsA also have psoriasis.

In the MEASURE 1 extension study, 80% of AS patients consistently achieved an ASAS 20 response (Assessment of Spondyloarthritis International Society response criteria) at 3 years. This was consistent with previous findings from the FUTURE 1 study in active PsA where Cosentyx demonstrated sustained improvements in the signs and symptoms of disease in approximately 80% of patients at 3 years as measured by ACR 20 response.